» Articles » PMID: 6133986

Early Aggressive Antihypertensive Treatment Reduces Rate of Decline in Kidney Function in Diabetic Nephropathy

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 1983 May 28
PMID 6133986
Citations 142
Authors
Affiliations
Soon will be listed here.
Abstract

The effect of early aggressive antihypertensive treatment on kidney function in diabetic nephropathy was studied prospectively in ten insulin-dependent diabetics (mean age 29 years). During the mean pretreatment period of 29 (range 23-38) months the glomerular filtration rate (GFR) decreased significantly and the urinary albumin excretion rate and arterial blood pressure rose significantly. During the 39 month (range 28-48) period of antihypertensive treatment with metoprolol, hydralazine, and frusemide (furosemide) or thiazide, arterial blood pressure fell from 144/97 mm Hg (mean of all pretreatment values) to 128/84 mm Hg (mean of all post-treatment values), urinary albumin excretion from 977 micrograms/min to 433 micrograms/min, and GFR from 80 to 62 ml/min/1 . 73 m2. The rate of decline in GFR decreased from 0.91 ml/min/month before treatment to 0.39 ml/min/month (range 0.08 to 0.68 ml/min/month) during treatment.

Citing Articles

Prognosis for Type 1 Diabetes with Diabetic Nephropathy between 2000 and 2020 - Changes in Kidney Function Decline Over Time and Development of Cardiovascular Disease, Kidney Failure, and Mortality.

Poulsen C, Jesse K, Carstensen B, Frimodt-Moller M, Hansen T, Persson F Kidney Int Rep. 2024; 9(12):3403-3413.

PMID: 39698347 PMC: 11652190. DOI: 10.1016/j.ekir.2024.09.010.


Progression and regression of kidney disease in type 1 diabetes.

Jansson Sigfrids F, Groop P Front Nephrol. 2024; 3:1282818.

PMID: 38192517 PMC: 10773897. DOI: 10.3389/fneph.2023.1282818.


Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease.

Jung C, Yoo T Diabetes Metab J. 2022; 46(2):181-197.

PMID: 35385633 PMC: 8987689. DOI: 10.4093/dmj.2021.0329.


Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.

Banerjee D, Winocour P, Chowdhury T, De P, Wahba M, Montero R BMC Nephrol. 2022; 23(1):9.

PMID: 34979961 PMC: 8722287. DOI: 10.1186/s12882-021-02587-5.


Sodium-Glucose Cotransporter 2 Inhibitors and the Kidney.

DeFronzo R, Abdul-Ghani M Diabetes Spectr. 2021; 34(3):225-234.

PMID: 34511848 PMC: 8387612. DOI: 10.2337/ds20-0071.